利用CRISPR基因编辑技术优化CAR T细胞疗法的疗效、安全性与可及性
本综述总结利用CRISPR系统改进CAR T细胞疗法的潜在用途,包括优化疗效与安全性、开发通用型CAR T细胞,并讨论CRISPR基因编辑面临的挑战及未来研究方向。
要点
- CRISPR技术可对CAR T细胞进行精确整合、多基因编辑和全基因组功能调控。
- 大规模gRNA遗传扰动CRISPR筛选为理解CAR T细胞抗癌机制提供无偏方法。
- 高特异性、可控性和高效性的新兴CRISPR工具可用于修饰CAR T细胞并识别新靶点。
核心结论
- CRISPR系统可用于优化CAR T细胞疗法的疗效与安全性,并开发通用型CAR T细胞。
- CRISPR基因编辑仍面临挑战,作者提出解决方案并指出未来研究方向。
研究设计与样本
- 综述,总结CRISPR系统在改进CAR T细胞疗法中的潜在用途。
主要发现
- CRISPR技术可有效执行精确整合、多基因编辑和全基因组功能调控等多种功能。
- 利用大规模gRNA遗传扰动的CRISPR筛选为理解CAR T细胞抗癌疗效机制提供无偏方法。
- 多种高特异性、可控性和高效性的新兴CRISPR工具有助于修饰CAR T细胞并识别新靶点。
局限性
- 原文报告CRISPR基因编辑面临挑战,作者提出解决方案并指出未来研究方向。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chimeric Antigen Receptor (CAR)-T-cell therapy has revolutionized cancer immune therapy. However, challenges remain including increasing efficacy, reducing adverse events and increasing accessibility. Use of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology can effectively perform various functions such as precise integration, multi-gene editing, and genome-wide functional regulation. Additionally, CRISPR screening using large-scale guide RNA (gRNA) genetic perturbation provides an unbiased approach to understanding mechanisms underlying anti-cancer efficacy of CAR T-cells. Several emerging CRISPR tools with high specificity, controllability and efficiency are useful to modify CAR T-cells and identify new targets. In this review we summarize potential uses of the CRISPR system to improve results of CAR T-cells therapy including optimizing efficacy and safety and, developing universal CAR T-cells. We discuss challenges facing CRISPR gene editing and propose solutions highlighting future research directions in CAR T-cell therapy.
引用
- Lei T, Wang Y, Zhang Y, et al. Leveraging CRISPR gene editing technology to optimize the efficacy, safety and accessibility of CAR T-cell therapy. Leukemia. 2024. PMID: 39455854. doi:10.1038/s41375-024-02444-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。